Drugs / Triplex
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04060277 | Nov 2019 → Jun 2023 overdue | Hodgkins lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, leukemia, myeloid, accelerated-phase +3 | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02506933 | Dec 2015 → Jan 2018 overdue | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, acute myeloid leukemia, cytomegalovirus infection +5 | City of Hope Medical Center | Active not recruiting | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triplex | “The Triplex vaccine is made up of 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) placed into a weakened virus called modified vaccinia Ankara (MVA)” NCT04060277 ↗1“Triplex is a recombinant attenuated poxvirus (modified vaccinia Ankara) expressing immunodominant CMV antigens.” PMID 32040960 ↗ Feb 2020 |
| Modality | Vaccine | “Triplex vaccine” NCT04060277 ↗ |
| Route | Intramuscular | “Intramuscular injections of Triplex or placebo were given on days 28 and 56 after HCT.” PMID 32040960 ↗ Feb 2020 |